Arrangements made between manufacturers and payers which are being implemented for innovative treatm...
Read moreNHS England is developing a new Commercial Framework, outlining potential opportunities for commerci...
Read moreZolgensma launched in May 2019 in the US for $2.1 million, whilst Zynteglo was launched in the EU in...
Read moreIn England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...
Read moreEnhancing Managed Entry Agreement capabilities through interactive workshops.
Read moreThis study investigates NICE evaluations of new cancer indications and legacy CDF indications (not p...
Read moreIncluded in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...
Read moreMEAs are also known by other names such as risk-sharing agreements, value-added services, and result...
Read more